Phase I Randomised Multi-Centre Study to Demonstrate the Safety of WBRT Concomitant to Intrathecal Liposomal Cytarabine (DepoCyte) Versus WBRT & Sequential Intrathecal Liposomal Cytarabine (DepoCyte) for Treatment of STNM With or Without Brain Metastasis.

Trial Profile

Phase I Randomised Multi-Centre Study to Demonstrate the Safety of WBRT Concomitant to Intrathecal Liposomal Cytarabine (DepoCyte) Versus WBRT & Sequential Intrathecal Liposomal Cytarabine (DepoCyte) for Treatment of STNM With or Without Brain Metastasis.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2013

At a glance

  • Drugs Cytarabine (Primary)
  • Indications Carcinomatous meningitis
  • Focus Adverse reactions
  • Sponsors Mundipharma International
  • Most Recent Events

    • 23 Oct 2012 Planned End Date changed from 1 Feb 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Feb 2011 Trial location (Austria) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top